Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. inflammatory cells
Show results for

Refine by

Inflammatory Cells Articles & Analysis

8 news found

Profacgen Updated Its E3 Ligase and Target Proteins Development Services

Profacgen Updated Its E3 Ligase and Target Proteins Development Services

As a major modulator of protein homeostasis, UPS is essential in signal transduction, mitophagy, DNA damage repair, inflammatory pathways, endocytosis, and cell cycle progression. More than 600 E3 ligases have been identified, only a few of which have been used in PROTAC design. ...

ByProfacgen


Immune-Onc Therapeutics Receives China Investigational New Drug (IND) Approval for the Phase 1 Study of IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4), in Patients with Solid Tumors

Immune-Onc Therapeutics Receives China Investigational New Drug (IND) Approval for the Phase 1 Study of IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4), in Patients with Solid Tumors

ABOUT LILRB2 (ILT4) LILRB2, also known as ILT4, is expressed mostly by myeloid cells, including monocytes, macrophages, dendritic cells, and neutrophils. ...

ByImmune-Onc Therapeutics, Inc.


Aurealis Therapeutics and Xbiome Enter into a License and Collaboration Agreement for Aurealis Four-in-One Diabetic Foot Ulcer and Inflammatory Disease Cell and Gene Therapy AUP-16 in Greater China

Aurealis Therapeutics and Xbiome Enter into a License and Collaboration Agreement for Aurealis Four-in-One Diabetic Foot Ulcer and Inflammatory Disease Cell and Gene Therapy AUP-16 in Greater China

Aurealis Therapeutics, a synthetic biology company developing groundbreaking four-in-one cell and gene therapies and Xbiome, an AI-based microbiome drug development company, today announced that the two companies have entered into an exclusive license and collaboration agreement for the clinical development and commercialization of Aurealis investigational Diabetic Foot Ulcer ...

ByAurealis Therapeutics


New, late-breaking data at EADV highlights emerging clinical profile of amlitelimab (formerly KY1005) in adults with inadequately controlled moderate-to-severe atopic dermatitis

New, late-breaking data at EADV highlights emerging clinical profile of amlitelimab (formerly KY1005) in adults with inadequately controlled moderate-to-severe atopic dermatitis

Amlitelimab is a fully human non-depleting monoclonal antibody that binds to OX40-Ligand, a key immune regulator, and has the potential to be a first-in-class treatment for a range of immune-mediated diseases and inflammatory disorders, including moderate-tosevere atopic dermatitis. By targeting OX40-Ligand, amlitelimab aims to restore immune homeostasis between ...

ByKiadis Pharma NV


Hydrogen Peroxide provides Clues to Immunity, Wound Healing, Tumor Biology - Puroxi

Hydrogen Peroxide provides Clues to Immunity, Wound Healing, Tumor Biology - Puroxi

Tumors and wounds both generate high levels of hydrogen peroxide, and immune cells responsible for inflammation seek out wounds as well as tumors. But inflammatory cells can often be detrimental. The cells can contribute to a tumor’s ability to grow and invade other tissue, and they can cause chronic inflammation at wound ...

ByPuroxi Pure Water Global Inc.


Kannalife, Inc. Announces Results from Comparative UVB-Radiation Study on Atopidine Versus CBD

Kannalife, Inc. Announces Results from Comparative UVB-Radiation Study on Atopidine Versus CBD

The Company has conducted scientific comparisons that have been made between two substances: cannabidiol (CBD), a non-psychoactive component of Cannabis, and Atopidine™, a novel, small molecule that has been shown in pre-clinical testing to have protective and anti-inflammatory properties. The inhibition of release of inflammatory substances from skin ...

ByNeuropathix, Inc.


Kannalife, Inc. Announces Results from Comparative UVB-Radiation Study on Atopidine Versus CBD

Kannalife, Inc. Announces Results from Comparative UVB-Radiation Study on Atopidine Versus CBD

The Company has conducted scientific comparisons that have been made between two substances: cannabidiol (CBD), a non-psychoactive component of Cannabis, and Atopidine™, a novel, small molecule that has been shown in pre-clinical testing to have protective and anti-inflammatory properties. The inhibition of release of inflammatory substances from skin ...

ByNeuropathix, Inc.


Lungpacer Medical, Inc. Presentations at American Thoracic Society Conference, Scheduled for May 2020, Philadelphia, Pennsylvania

Lungpacer Medical, Inc. Presentations at American Thoracic Society Conference, Scheduled for May 2020, Philadelphia, Pennsylvania

Increased Presence of Neural Pro-Inflammatory Cells in the Hippocampus After 50 Hours of Gold-Standard Mechanical Ventilation in a Pre-Clinical Pig Model, Bassi, T., et al. ...

ByLungpacer Medical Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT